Gastroenterology and Hepatology

Episodes 31-45 of 62

• 

  MinuteCE®

  Addressing the Core Unmet Needs to Our Approach for Hepatic Encephalopathy

  • 

    

    Robert Rahimi, MD, MSCR

    Peer

  • 

    

    Arun B. Jesudian, MD

    Peer

  • 

    

    Patricia P. Bloom, MD

    Peer

  1.25 credits 8 episodes

• 

  RestartResume

  The Unmet Need for HE Therapy in the African American Community – Why Is This a Concern?

  MinuteCE®

  The Unmet Need for HE Therapy in the African American Community – Why Is This a Concern?

  • 

    

    Patricia P. Bloom, MD

    Peer

  1.25 program credits

• 

  RestartResume

  How Do I Prevent Future Hospital Visits due to HE?

  MinuteCE®

  How Do I Prevent Future Hospital Visits due to HE?

  • 

    

    Patricia P. Bloom, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Equitable HEalth for All: Improving Care for Underserved Populations and Their Unmet Needs

  MinuteCE®

  Equitable HEalth for All: Improving Care for Underserved Populations and Their Unmet Needs

  • 

    

    Patricia P. Bloom, MD

    Peer

  • 

    

    Robert Rahimi, MD, MSCR

    Peer

  1.25 program credits

• 

  RestartResume

  HElp! AASLD Guidelines Related to Diagnosis of HE

  MinuteCE®

  HElp! AASLD Guidelines Related to Diagnosis of HE

  • 

    

    Robert Rahimi, MD, MSCR

    Peer

  1.25 program credits

• 

  RestartResume

  West HavEn Criteria—Meaningfulness Into Clinical Practice

  MinuteCE®

  West HavEn Criteria—Meaningfulness Into Clinical Practice

  • 

    

    Arun B. Jesudian, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Collaboration and Management of HE: Establishing Foundation for Successful Outcomes

  MinuteCE®

  Collaboration and Management of HE: Establishing Foundation for Successful Outcomes

  • 

    

    Arun B. Jesudian, MD

    Peer

  • 

    

    Robert Rahimi, MD, MSCR

    Peer

  1.25 program credits

• 

  RestartResume

  Practical Management of Variceal Bleeding and Hepatorenal Syndrome

  CME/CE

  Practical Management of Variceal Bleeding and Hepatorenal Syndrome

  • 

    

    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA

    Peer

  • 

    

    Andrew Keaveny, MD

    Peer

  • 

    

    Don Rockey, MD

    Peer

  0.50 credits

• 

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

  MinuteCE®

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?

  • 

    

    Yelena Janjigian, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers

  MinuteCE®

  Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers

  • 

    

    Samuel J. Klempner, MD

    Peer

  1.25 program credits

• 

  RestartResume

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  MinuteCE®

  What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?

  • 

    

    Yelena Janjigian, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress

  MinuteCE®

  Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress

  • 

    

    Yelena Janjigian, MD

    Peer

  1.25 program credits

• 

  RestartResume

  HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

  MinuteCE®

  HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity

  • 

    

    Yelena Janjigian, MD

    Peer

  1.25 program credits

• 

  MinuteCE®

  Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies

  • 

    

    Yelena Janjigian, MD

    Peer

  • 

    

    Samuel J. Klempner, MD

    Peer

  1.25 credits 11 episodes

• 

  RestartResume

  What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers

  MinuteCE®

  What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers

  • 

    

    Samuel J. Klempner, MD

    Peer

  1.25 program credits

• Prev
• 1
• 2
• 3
• 4
• 5
• Next